Global Generic Oncology Drug Market Share, Size and Forecast 2017-2022

1

Global Generic Oncology Drug Market Share, Size
and Forecast 2017-2022
Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Generic Oncology Drug Market Catalysed by
Increasing Number of Cancer Patients The global
generic oncology drug market has experienced a
significant growth in recent years. The primary
factor influencing the demand for generic
oncology drugs is rise in the population of
cancer patients. As a result of this, several
healthcare organisations are encouraging the use
of these drugs. The latest report by IMARC Group
titled, Generic Oncology Drug Market Global
Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2017-2022, finds that the global
generic oncology drug market reached a value of
more than US 18 Billion in 2016, growing at a
CAGR of around 12 during 2009-2016. Generic
drugs account for almost 80 of the total
prescriptions across different medical
specialties. After branded drugs go off-patent,
manufacturers in the pharmaceuticals industry
secure the right to develop and sell a generic
version of those drugs. Generic drugs carry the
same functional properties as their branded
counterparts. Additionally, these are available
in the market at a much cheaper price almost
one-tenth of the branded drug. Currently, there
is a high demand for generic oncology drugs as a
result of a growth in the number of cancer
patients across the globe. Some of most commonly
diagnosed cancers around the world include lung,
breast, and colorectum cancers.
4
Report Description and Highlights
Report Description
Request sample of the report http//www.imarcgrou
p.com/request?typereportid545flagB Highlight
s of the global generic oncology drug
market The market is driven by active
participation of the healthcare
organisations. The market is bifurcated broadly
as imatinib tablets and paclitaxel
injectables. The market is expected to reach a
value of more than US 32 Billion by 2022. To
get more information, please visit _at_
http//www.imarcgroup.com/generic-oncology-drug-ma
nufacturing-plant According to a research, in
2015 nearly 15 Million patients were diagnosed
with cancer, among which more than 8 Million lost
their lives to it. The major causes of the
dissemination of cancer on such a wide scale are
lack of awareness and high costs of treatment.
Most patients, particularly in the developing
regions, do not have access to expensive drugs
and therapies that are required to cure cancer.
Due to this, manufacturing of generic oncology
drugs is promoted by both, government and
non-government health organisations in order to
provide treatment to the maximum number of people
at affordable rate. Further, the market is
expected to reach a value of more than US 32
Billion by 2022.
5
Report Description and Highlights
Report Description

• The market is segmented on the basis of product
  type including imatinib tablet and paclitaxel
  injectable. The market is also segmented on the
  basis of key regions. Some of the major markets
  for generic oncology drugs are the USA, China,
  Brazil, Germany, and France. An analysis of the
  competitive landscape provides the details of the
  key players operative in the market. Some of the
  major players are Teva Pharmaceuticals,
  Novartis-Sandoz, Mylan, Freseunis, and Hospira.
• The report by IMARC Group has examined the global
  generic oncology drug market on the basis of
• Product Type
• Imatinib Tablet
• Paclitaxel Injectable
• Key Regions
• USA
• China
• Brazil

6
Report Description and Highlights
Report Description

• Germany
• France
• Key Players
• Teva Pharmaceuticals
• Novartis-Sandoz
• Mylan
• Freseunis
• Hospira
• Related Reports
•  
• Brazil Generic Drug Market _at_ http//www.imarcgroup
  .com/brazil-generic-drug-market
• US Generic Drug Market _at_ http//www.imarcgroup.com
  /us-generics-market

7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us